Clinical Trials | October 16, 2025
Merck’s DOR/ISL regimen shows minimal impact on weight and lipids in phase 3 HIV studies
These findings follow positive Phase 3 results presented earlier this year
These findings follow positive Phase 3 results presented earlier this year
The conference stressed a multi-dimensional approach required to address Antimicrobial Resistance (AMR), focusing on the right approach and strengthening awareness
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
AstraZeneca Pharma India discontinues manufacturing of Imdur
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
This facility represents a significant step in Croda’s Pharma business strategy to ‘Empower biologics delivery’
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
The emergence of new infections in India is a growing concern
Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain
Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery
Subscribe To Our Newsletter & Stay Updated
